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Glycopeptides (vancomycin and teicoplanin) represent the
gold standard for therapy of invasive infections caused
by multidrug-resistant Staphylococcus aureus, most notably
hospital-acquired methicillin-resistant S. aureus (MRSA).
Reports of increasing in vitro resistance to glycopeptides
combined with reports of clinical failures underscore the
need for alternative therapies. Older agents with favorable
in vitro potency available in oral and/or intravenous
forms include trimethoprim-sulfamethoxazole, rifampin,
fusidic acid, fosfomycin, and clindamycin. However, limited
clinical data exist to support their routine use as initial
therapy in the treatment of invasive disease. Newer
treatment options for MRSA include linezolid, quinupristin-
dalfopristin, daptomycin, cftobiprole, tigecycline, and
nemonoxacin. With the exception of linezolid, these newer
agents require intravenous administration. Combination
therapy is mandatory for selected invasive diseases
refractory to standard monotherapies. These diseases
include endocarditis, meningitis, septic arthritis, prosthetic
device infections, and other recalcitrant MRSA Infections.
Some novel agents are under investigation, consisting
of oritavancin, dalbavancin, telavancin, and ceftobiprole.
Daptomycin is a promising antibiotic for the treatment of
patients with right-sided endocarditis and bacteraemia.
However, development of hematogenous spread of MRSA
resulting in multiple lung abscesses during daptomycin
treatment for bacteremia and right-sided endocarditis
and treatment failure for infective endocarditis due
to daptomycin-nonsusceptible MRSA have been reported.
Routinely tests of the daptomycin susceptibility is necessary
before the use as a rescue therapy for persistent
MRSA infection and difﬁcult-to-eradicate infectious foci
especially after a prolonged glycopeptide therapy. To
prevent prolonged glyopeptide therapy, using the maximum
tolerated dose of glycopeptide and aggressive adjnctive
therapies such as surgical interventions to remove culprit
foci are the best strategy for the treatment of recalcitrant
MRSA infections.
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In patients and animal models with cirrhosis, the
heart is abnormal. Although the circulation becomes
hyperdynamic, manifested as increased cardiac output
and decreased peripheral vascular resistance and
arterial pressure, the heart responds subnormally to
numerous stimuli/stresses. Cardiac ventricular function
under physiological, pharmacological or surgical stress
is blunted, with abnormalites of both systolic and
diastolic function. This condition is known as cirrhotic
cardiomyopathy. Other features of the syndrome include:
(a) electrophysiological changes in repolarization including
prolonged electrocardiographic QT interval and a curious
dissynchrony in the normally tightly-regulated time interval
between electrical and mechanical onset of systole,
(b) enlargement or hypertrophy of cardiac chambers,
(c) markers of cardiac ‘distress’ such as BNP or pro-BNP
and troponin I.
Although these changes when initially described almost
4 decades ago were ascribed to a mild or latent form
of alcoholic cardiotoxicity, it is now incontrovertibly
established that the condition of cirrhosis per se is
associated with this, as patients and animal models
with non-alcoholic cirrhosis show the same pattern
or cardiac dysfunction. Recent evidence implicates a
signiﬁcant pathogenic role of this syndrome in the
development of acute hepatorenal syndrome after
spontaneous bacterial peritonitis and poor outcomes such
as increased mortality/morbidity after challenges such as
TIPS insertion and liver transplantation. It may also explain
the uncommon but mysterious and inexplicable onset of
heart failure in the peri- and post-transplantation period
in patients with no previous history of heart disease or
dysfunction.
Several pathogenic mechanisms have been described
including: dysfunction or defects in the cardiac b-adrenergic
receptor system, plasma membrane physico-chemical milieu
(decreased membrane biophysical ﬂuidity due to an
increased cholesterol:phospholipid ratio in the plasma
membrane lipid bilayer), membrane calcium channels, and
humoral factors such as cytokines, nitric oxide, carbon
monoxide and endogenous cannabinoids. Many of these
pathogenic mechanisms are inter-related and their exact
relationship is the subject of ongoing research.
Treatment strategies for cirrhotic cardiomyopathy remain
unclear. Fortunately over heart failure is distinctly
uncommon. Repolarization abnormalities such as QT
prolongation may respond to b-blockade. Promising avenues
of inquiry include cardiac anti-ﬁbrogenic therapies such
as angiotensin converting enzyme inhibitors. Cirrhotic
cardiomyopathy is a previously underappreciated syndrome
with important clinical consequences in patients with
cirrhosis, especially given the emergence of liver
transplantation as effective therapy for endstage liver
disease.
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Infection and cerebral edema are the two most common
fatal complications of acute liver failure (ALF). ALF is a
state of immunosuppression. In addition there are frequent
breaches of the skin and mucus membrane barriers, and
need for invasive treatments and monitoring. Development
of infection at any site during grade I or II encephalopathy
(HE) is an independent risk factor for worsening of HE grade.
In addition, infection can directly aggravate liver damage,
and increases mortality in ALF.
Clinical signs such as high temperature and leukocyte
count may be absent in 30% of ALF patients, and
daily microbiological surveillance is recommended. An 80%
infection rate has been reported from the west. Over
70% of the isolates in the west, were Gram-positive
organisms. In our center, the infection rate of ALF patients
is around 60% and 80% of our isolates are Gram-negative.
The most common isolates are Acinetobacter baumanni,
Klebsiella pneumonia, Escherichia coli, and Pseudomonas
aeruginosa. We found that 94.7% Gram-negative isolates
were ESBL positive, and 66.7% Gram-positive isolates
were Methicillin resistant. In addition we had a 12.5%
fungemia rate with Aspergillus spp. and tropicalis and
glabrata species of Candida being the most common
isolates. Western series have reported fungemia rates of
